Pancreastatin: Multiple Actions on Human Intermediary Metabolism<i>in Vivo</i>, Variation in Disease, and Naturally Occurring Functional Genetic Polymorphism

Abstract

The dysglycemic peptide pancreastatin is specifically and potently active in humans on multiple facets of intermediary metabolism, although it did not antagonize insulin. Pancreastatin is elevated in diabetes, and the variant Gly297Ser had increased potency to inhibit glucose uptake. The importance of human pancreastatin in vivo as well as its natural variants is established.